For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.

Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

NEW YORK – Singapore's Ministry of Health announced this week it will launch a genetic testing program to improve diagnosis of familial hypercholesterolemia (FH) as part of a broader national focus on ...

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

Lyell Immunopharma announced new clinical data Tuesday from a Phase I/II trial of its dual-targeted CD19/CD20 CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. The company ...

The decision comes as the company is discontinuing clinical testing of a CLDN6-targeted CAR T-cell therapy in testicular cancer.

The US subsidiary will focus on advancing PolTreg's pipeline in these new territories, including its lead candidate PTG-007 in type 1 diabetes.

The biotech plans to use one-year follow-up data from the Phase II/III trial to support a biologics license application for OCU410ST in 2027.

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.

NEW YORK – Agenus and Noetik on Tuesday said they are working together to develop predictive biomarkers of response for Agenus' investigational immuno-oncology combination, botensilimab and ...